CSF2 and COVID-19: There is a granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody, Lenzilumab, which is being tested (Phase III clinical trial) for prevention of respiratory failure and/or death in COVID-19 patients [139].